Anavex Life Sciences Corp (AVXL)

[jimmy667]

What are the chances of approval for A2-73 in ALZ if an FDA agreed end point for approval is resolution of insomnia symptoms for those ALZ patients with insomnia? What of other quality of life issues, irritability, sociability better mood less confusion.?
These are for the most part elderly and most of the time not trying to return them to the work force so cognition should not have primacy, rather quality of life should be the main focus. Memory and cognition improvements would be nice but quality of life can be improved independently of these hard to measure and improve targets.
Another question to ponder. When it becomes apparent that that Anavex has a 50% chance of becoming a 10 bagger does it quickly become a 5 bagger on these newly factored better odds for approval?
Or as others have quite rightly said AVXL will get a big boost in share price when the trials are announced along with the primary and secondary endpoints targeted for approval.